Singapore invests $37.1m for precision oncology research

Two research programmes on lymphoma and colorectal cancer have received $18.5m (S$25m) each.

The Ministry of Health (MoH). through the National Medical Research Council (NMRC), Office, MOH Holdings, Pte Ltd, has invested $37.1m (S$50m) to advance precision oncology research in Singapore.

The investment, under the NMRC Open Fund-Large Collaborative Grant (OF-LCG) programme, supports two multi-institution and multidisciplinary teams, each receiving a grant of $18.5m (S$25m) for their research programmes.

ALSO READ: Singapore healthcare needs collective and progressive action for sustainability

One of the programmes, “SYMPHONY 2.0,” led by the National Cancer Centre Singapore (NCCS), aims to develop cost-effective, accessible, and new treatment modalities to address Asian-centric lymphomas.

Meanwhile, the “Colo-SCRIPT” programme co-led by NCCS and A*STAR will focus on colorectal cancer through a subtype-specific approach to implement prevention and early detection strategies, and test novel therapies in clinical trials.

S$1 = $0.74